Ebola Treatment Shown to Work on Infected Monkeys

Global Security Newswire Staff
Add to Briefcase
See more stories about...
Global Security Newswire Staff
Aug. 22, 2013, 9:02 a.m.

A new Ebola drug grown from spe­cial to­bacco plants has been shown to cure mon­keys that were already dis­play­ing signs of in­fec­tion by the vir­al hem­or­rhagic fever, the Los Angeles Times re­por­ted on Wed­nes­day.

Oth­er Ebola coun­ter­meas­ures have been shown to work on in­fec­ted an­im­als be­fore they start dis­play­ing symp­toms of the highly vir­u­lent and leth­al dis­ease. However, this is the first time a drug has demon­strated any ef­fect­ive­ness after signs of the vir­us have mani­fes­ted. That is re­garded as a cru­cial cap­ab­il­ity in the event of a real-life dis­ease epi­dem­ic, ac­cord­ing to vir­o­lo­gist Gene Olinger, who works at the Army Med­ic­al Re­search In­sti­tute of In­fec­tious Dis­eases at Fort De­t­rick, Md.

“We’ve pushed the op­por­tun­ity to treat people to the point where they walk in and say, ‘I have a fever,’” said Olinger, co-au­thor of a re­port on the new Ebola drug pub­lished by the Sci­ence Trans­la­tion­al Medi­cine journ­al on Wed­nes­day. “A lot of folks in the field would have thought pro­tect­ing an an­im­al at the time of fever and viremia is too late to have a clin­ic­al be­ne­fit.”

Ebola is one of the most deadly and con­ta­gious dis­eases known to ex­ist in nature. The lack of ad­equate vac­cines and an­ti­dotes for the dis­ease have made it a ser­i­ous worry for biode­fense spe­cial­ists con­cerned about its pos­sible ap­plic­a­tions as a bio­lo­gic­al weapon.

In the re­cent study, sev­en in­fec­ted rhesus mon­keys were ad­min­istered the ex­per­i­ment­al treat­ment MB-003 through their veins once every three days. Three of the mon­keys did not die, res­ult­ing in a stat­ist­ic­ally not­able suc­cess rate of 43 per­cent.

Fort De­t­rick sci­ent­ist and lead study au­thor James Pet­titt said it is prob­able that in a real-life out­break, the drug would be ad­min­istered at a high­er dosage and with great­er fre­quency.

“We think we’ll get bet­ter res­ults,” the re­search­er said.

Grow­ing the drug from spe­cially de­veloped to­bacco leaves is not only less costly than con­ven­tion­al cell-based meth­ods, but also al­lows for large batches of the drug to be pro­duced on fairly short, weeklong sched­ules, ac­cord­ing to the Times art­icle.

Olinger said fur­ther meas­ures will be taken to im­prove MB-003 by adding to it more Ebola an­ti­bod­ies that were dis­covered by a dif­fer­ent group of re­search­ers.

What We're Following See More »
AN ASTOUNDING OUTCOME
AP Calls Election for Doug Jones
5 hours ago
WHY WE CARE
INVESTIGATED RUSSIA UNTIL SUMMER
FBI Agents Called Trump an “Idiot” and “Loathsome”
6 hours ago
THE LATEST
LOWER TOP INDIVIDUAL TAX RATE
GOP Could Raise Corporate Tax Rate
11 hours ago
THE DETAILS

"Republican negotiators have a tentative agreement to raise the corporate tax rate in their joint House-Senate tax bill from 20 to 21 percent, two GOP sources tell The Hill ... Another key change in the mix would lower the top rate for individuals from 39.6 percent to 37 percent."

Source:
AT 10 AM
Franken Replacement to Be Announced Tomorrow
13 hours ago
THE LATEST
PER MCCONNELL
AL Senate Winner Won’t Be Seated Before 2018
13 hours ago
THE LATEST
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login